Proteinase-Activated Receptor-2 (PAR2): Vascular Effects of a PAR2-Derived Activating Peptide via a Receptor Different than PAR2
Authors:
- 1 January 2002
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 303 (3) , 985-992
Abstract
We studied the actions of the proteinase-activated receptor-2-activating peptide (PAR2-AP)trans-cinnamoyl-LIGRLO-amide (tc-LI) in femoral (FA), renal, and small mesenteric (MA) arterial vessels from C57BL/6 [PAR2 (+/+)] and PAR2 (−/−) mice. The actions of tc-LI were compared with those of the parent PAR2-AP Ser-Leu-Ile-Gly-Arg-Leu-amide (SLIGRL-amide; SLI-NH2). Either SLI-NH2 or tc-LI (0.1–10 μM) induced relaxation of either 9,11-dideoxy-9α,11α-methanoepoxy-prosta-5Z,13E-dien-1-oic acid (U46619)- or cirazoline-precontracted FA from PAR2 (+/+) in endothelium-intact preparations but did not relax vessels from PAR2 (−/−) mice. This FA relaxation by SLI-NH2 and by tc-LI was inhibited by 1) pretreatment with a combination ofl-NG-nitroarginine methyl ester (l-NAME) and 1H-[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 2) precontraction with 30 mM KCl, or 3) removal of the endothelium. In contrast, tc-LI caused anl-NAME/ODQ/indomethacin-resistant relaxation of MA from PAR2 (+/+) mice. In contrast with SLI-NH2, tc-LI (>30 μM) contracted arteries from both PAR2 (−/−) and PAR2 (+/+) mice. Pretreatment of tissues with a combination of cyclopiazonic acid plus caffeine reduced significantly tc-LI-induced contractions, whereas nifedipine, CdCl2, and Ca2+-free conditions did not. Inhibitors of vascular muscarinic, α1-adrenergic, neurokinin, thromboxane A2, histamine, angiotensin II, or endothelin-1 receptors failed to inhibit contractions by 50 μM tc-LI. At resting tension, SLI-NH2 (>10 μM) contracted all arteries in an endothelium-independent manner but only from PAR2 (+/+) mice. We conclude that the endothelium-dependent vasodilation initiated by SLI-NH2 and tc-LI, but not the endothelium-independent contraction initiated by tc-LI, are due to the activation of PAR2. Indeed, the data from PAR2 (−/−) mice indicate that tc-LI, in addition to activating PAR2, is an agonist of vascular smooth muscle contraction via a receptor different than PAR2.Keywords
This publication has 32 references indexed in Scilit:
- International Union of Pharmacology. XXVIII. Proteinase-Activated ReceptorsPharmacological Reviews, 2002
- Mechanisms of action of proteinase‐activated receptor agonists on human plateletsBritish Journal of Pharmacology, 2002
- Protease activated receptor 2 and the cardiovascular systemBritish Journal of Pharmacology, 2002
- Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptidesCanadian Journal of Physiology and Pharmacology, 2001
- Protease-activated Receptors in Vascular BiologyThrombosis and Haemostasis, 2001
- Structure-Function Analysis of Protease-activated Receptor 4 Tethered Ligand PeptidesJournal of Biological Chemistry, 2000
- Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptidesCanadian Journal of Physiology and Pharmacology, 1997
- Ligand Cross-reactivity within the Protease-activated Receptor FamilyJournal of Biological Chemistry, 1996
- Development of Potent Thrombin Receptor Antagonist PeptidesJournal of Medicinal Chemistry, 1996
- Expression Cloning and Characterization of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor ActivationSeminars in Thrombosis and Hemostasis, 1992